Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 60,099 | 54,268 | 48,065 | 40,638 | 44,390 |
| Cost of Goods | 9,478 | 13,593 | 7,790 | 5,971 | 7,570 |
| Gross Profit | 50,621 | 40,675 | 40,275 | 34,667 | 36,820 |
| Operating Expenses | 49,420 | 54,161 | 49,252 | 49,883 | 47,231 |
| Operating Income | 1,679 | -12,893 | -8,187 | -14,245 | -9,841 |
| Interest Expense | 7,703 | 7,786 | 7,964 | 7,032 | 7,018 |
| Other Income | 911 | 1,617 | 1,895 | 2,604 | 3,233 |
| Pre-tax Income | -5,113 | -19,062 | -14,256 | -18,673 | -13,626 |
| Income Tax | 0 | -3,324 | 749 | 307 | -236 |
| Net Income Continuous | -5,113 | -15,738 | -15,005 | -18,980 | -13,390 |
| Net Income | $-5,113 | $-15,738 | $-15,005 | $-18,980 | $-13,390 |
| EPS Basic Total Ops | -0.02 | -0.11 | -0.10 | -0.14 | -0.10 |
| EPS Basic Continuous Ops | -0.03 | -0.11 | -0.10 | -0.14 | -0.10 |
| EPS Diluted Total Ops | -0.02 | -0.11 | -0.10 | -0.14 | -0.10 |
| EPS Diluted Continuous Ops | -0.03 | -0.11 | -0.10 | -0.14 | -0.10 |
| EPS Diluted Before Non-Recurring Items | -0.03 | -0.06 | -0.10 | N/A | N/A |
| EBITDA(a) | $5,636 | $-8,484 | $-4,708 | $-10,458 | $-6,055 |